Benzinga | May 4, 2021 06:35AM EDT

RBC Capital Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $110

RBC Capital analyst Luca Issi initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Outperform rating and announces Price Target of $110.